Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

EARLY COLORECTAL CANCER: PATIENT-TARGETED AND ORGAN PRESERVING TREATMENT ECOPOP

Project description

Less invasive treatment for early colorectal cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in Europe. While screening programmes facilitate early detection, traditional surgical treatments can be overly invasive, particularly for elderly patients. Advances in flexible endoscopy have enabled local tumour removal, but long-term data comparing its outcomes to surgery remain insufficient. The EU-funded ECOPOP project will evaluate the efficacy and safety of endoscopic removal for early-stage CRC through three randomised trials. The project seeks to establish criteria for identifying high-risk lesions using novel biomarkers, advanced endoscopic imaging, and an AI-guided treatment algorithm. By offering less invasive treatment options, addressing patient preferences, and supporting cost-effectiveness analyses, ECOPOP aims to influence clinical practice guidelines and improve care for CRC patients.

Objective

Incidence and mortality of colorectal cancer (CRC) is the second leading cause of cancer death in Europe. With current screening programs in most European countries, many CRCs are detected in an early and curable stage with excellent prognosis. The current standard treatment for early CRC is surgical tumour removal. This is considered as overly invasive especially for the growing number of elderly and frail patients. Expanding technical possibilities of local tumour removal by flexible endoscopy along with initial data supporting its oncological safety open the way to organ preserving therapy. This may result in avoiding surgery and improved patients´ quality of life (QoL). However, high-quality, long-term oncological outcome data of endoscopic removal as compared to surgery are lacking, and precise oncological risk criteria prior to the start of the therapy are urgently needed. The current project has two major aims: a) to assess oncological efficacy, safety, and patient QoL of local endoscopic removal of early CRC as compared to surgery in 3 randomized trials, and b) to develop and test criteria in this patient population to primarily identify high-risk lesions based on novel biomarkers, endoscopic imaging, and other clinical criteria, also within an artificial intelligence-guided treatment algorithm. We propose to provide state-of-the-art assessment of new, sustainable, less invasive treatment modalities for early-stage CRC and determine patient preferences around these therapies. We will perform large, international head-to-head randomized clinical trials. These trials will allow carbon cost effectiveness analyses, biomarker research and development of clinical practice guidelines to carve out the next-generation best clinical practice for patients with early-stage CRC. Our proposal aims at less invasive, sustainable organ-preserving therapies maintaining high oncological efficacy and helping physicians and patients to perform individual shared decision-making.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Coordinator

UNIVERSITETET I OSLO
Net EU contribution
€ 1 122 420,00
Total cost
No data

Participants (16)

Partners (1)

My booklet 0 0